Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 925 to 936 of 936 entries
Sorted by: Best Match Show Resources per page
[Management of toxicities from immunotherapy].

Deutsche medizinische Wochenschrift (1946)

Heinrich K, von Bergwelt-Baildon M, Theurich S.
PMID: 34448188
Dtsch Med Wochenschr. 2021 Sep;146(17):1119-1128. doi: 10.1055/a-1303-8780. Epub 2021 Aug 26.

Immunotherapy with checkpoint inhibitors - monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) or the programmed death-1 receptor (PD-1) and its ligand PD-L1 - is now standard of care in the treatment of patients with various tumor types....

Cite
Heinrich K, von Bergwelt-Baildon M, Theurich S. Nebenwirkungsmanagement von Immuncheckpoint-Inhibitor-Therapien. [Management of toxicities from immunotherapy]. Dtsch Med Wochenschr. 2021;146(17):1119-1128doi: 10.1055/a-1303-8780.
Heinrich, K., von Bergwelt-Baildon, M., & Theurich, S. (2021). Nebenwirkungsmanagement von Immuncheckpoint-Inhibitor-Therapien. [Management of toxicities from immunotherapy]. Deutsche medizinische Wochenschrift (1946), 146(17), 1119-1128. https://doi.org/10.1055/a-1303-8780
Heinrich, Kathrin, et al. "Nebenwirkungsmanagement von Immuncheckpoint-Inhibitor-Therapien." [Management of toxicities from immunotherapy]. Deutsche medizinische Wochenschrift (1946) vol. 146,17 (2021): 1119-1128. doi: https://doi.org/10.1055/a-1303-8780
Heinrich K, von Bergwelt-Baildon M, Theurich S. Nebenwirkungsmanagement von Immuncheckpoint-Inhibitor-Therapien. [Management of toxicities from immunotherapy]. Dtsch Med Wochenschr. 2021 Sep;146(17):1119-1128. doi: 10.1055/a-1303-8780. Epub 2021 Aug 26. German. PMID: 34448188.
Copy Download .nbib Format: NLM
Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.

Current pediatric reviews

Leung AKC, Lam JM, Alobaida S, Leong KF, Wong AHC.
PMID: 33902423
Curr Pediatr Rev. 2021 Apr 25; doi: 10.2174/1573396317666210426105045. Epub 2021 Apr 25.

BACKGROUND: Juvenile dermatomyositis is the most common inflammatory myopathy in the pediatric age group and a major cause of mortality and morbidity in individuals with childhood rheumatic diseases. Mounting evidence suggests that early diagnosis and timely aggressive treatment are...

Cite
Leung AKC, Lam JM, Alobaida S, et al. Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management. Curr Pediatr Rev. 2021;doi: 10.2174/1573396317666210426105045.
Leung, A. K. C., Lam, J. M., Alobaida, S., Leong, K. F., & Wong, A. H. C. (2021). Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management. Current pediatric reviews, . https://doi.org/10.2174/1573396317666210426105045
Leung, Alexander K C, et al. "Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management." Current pediatric reviews vol. (2021). doi: https://doi.org/10.2174/1573396317666210426105045
Leung AKC, Lam JM, Alobaida S, Leong KF, Wong AHC. Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management. Curr Pediatr Rev. 2021 Apr 25; doi: 10.2174/1573396317666210426105045. Epub 2021 Apr 25. PMID: 33902423.
Copy Download .nbib Format: NLM
[Strategies for effective treatment of ANCA-associated vasculitides with fewer side effects].

Der nephrologe

Schönermarck U, Vielhauer V.
PMID: 34484454
Nephrologe. 2021 Aug 30;1-12. doi: 10.1007/s11560-021-00527-w. Epub 2021 Aug 30.

The pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides is complex; however, a better understanding in recent years has enabled new therapeutic approaches. In recent years priority was given to the minimization of treatment-associated toxicity. For induction of remission of...

Cite
Schönermarck U, Vielhauer V. Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden. [Strategies for effective treatment of ANCA-associated vasculitides with fewer side effects]. Nephrologe. 2021;1-12doi: 10.1007/s11560-021-00527-w.
Schönermarck, U., & Vielhauer, V. (2021). Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden. [Strategies for effective treatment of ANCA-associated vasculitides with fewer side effects]. Der nephrologe, 1-12. https://doi.org/10.1007/s11560-021-00527-w
Schönermarck, Ulf, and Vielhauer, Volker. "Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden." [Strategies for effective treatment of ANCA-associated vasculitides with fewer side effects]. Der nephrologe vol. (2021): 1-12. doi: https://doi.org/10.1007/s11560-021-00527-w
Schönermarck U, Vielhauer V. Strategien zur effektiven und nebenwirkungsarmen Therapie ANCA-assoziierter Vaskulitiden. [Strategies for effective treatment of ANCA-associated vasculitides with fewer side effects]. Nephrologe. 2021 Aug 30;1-12. doi: 10.1007/s11560-021-00527-w. Epub 2021 Aug 30. German. PMID: 34484454; PMCID: PMC8404175.
Copy Download .nbib Format: NLM
Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series.

Rheumatology (Oxford, England)

Zhang H, Sun Y, Liu H, Cheng X, Ye J, Hu Q, Jia J, Wang M, Liu T, Zhou Z, Yang C, Chi H, Teng J, Su Y.
PMID: 34508561
Rheumatology (Oxford). 2021 Sep 11; doi: 10.1093/rheumatology/keab629. Epub 2021 Sep 11.

OBJECTIVES: To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody.METHODS: Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at...

Cite
Zhang H, Sun Y, Liu H, et al. Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series. Rheumatology (Oxford). 2021;doi: 10.1093/rheumatology/keab629.
Zhang, H., Sun, Y., Liu, H., Cheng, X., Ye, J., Hu, Q., Jia, J., Wang, M., Liu, T., Zhou, Z., Yang, C., Chi, H., Teng, J., & Su, Y. (2021). Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series. Rheumatology (Oxford, England), . https://doi.org/10.1093/rheumatology/keab629
Zhang, Hao, et al. "Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series." Rheumatology (Oxford, England) vol. (2021). doi: https://doi.org/10.1093/rheumatology/keab629
Zhang H, Sun Y, Liu H, Cheng X, Ye J, Hu Q, Jia J, Wang M, Liu T, Zhou Z, Yang C, Chi H, Teng J, Su Y. Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series. Rheumatology (Oxford). 2021 Sep 11; doi: 10.1093/rheumatology/keab629. Epub 2021 Sep 11. PMID: 34508561.
Copy Download .nbib Format: NLM
Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update.

World journal of stem cells

Akbulut G, Yesildemir O.
PMID: 34786156
World J Stem Cells. 2021 Oct 26;13(10):1530-1548. doi: 10.4252/wjsc.v13.i10.1530.

The coronavirus disease 2019 (COVID-19) is caused by the newly discovered SARS-CoV-2. Hematopoietic stem cell transplantation (HSCT) is a high-risk procedure. The novelty of COVID-19 has created more uncertainty during all phases of HSCT. It is thought that HSCT...

Cite
Akbulut G, Yesildemir O. Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update. World J Stem Cells. 2021;13(10):1530-1548doi: 10.4252/wjsc.v13.i10.1530.
Akbulut, G., & Yesildemir, O. (2021). Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update. World journal of stem cells, 13(10), 1530-1548. https://doi.org/10.4252/wjsc.v13.i10.1530
Akbulut, Gamze, and Yesildemir, Ozge. "Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update." World journal of stem cells vol. 13,10 (2021): 1530-1548. doi: https://doi.org/10.4252/wjsc.v13.i10.1530
Akbulut G, Yesildemir O. Overview of nutritional approach in hematopoietic stem cell transplantation: COVID-19 update. World J Stem Cells. 2021 Oct 26;13(10):1530-1548. doi: 10.4252/wjsc.v13.i10.1530. PMID: 34786156; PMCID: PMC8567455.
Copy Download .nbib Format: NLM
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency.

Hematology reports

Palandri F, Polverelli N, Lifrieri F, Catani L, Giannini MB, Baccarani M, Vianelli N.
PMID: 22826792
Hematol Rep. 2012 May 10;4(2):e10. doi: 10.4081/hr.2012.e10. Epub 2012 Jun 26.

Immunosuppressive agents are the standard therapeutic approach for immune thrombocy-topenia (ITP). Their prolonged use may increase the risk of infectious complications, particularly when the patient is already at higher infectious risk. In this setting, the use of drugs with...

Cite
Palandri F, Polverelli N, Lifrieri F, et al. Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency. Hematol Rep. 2012;4(2):e10doi: 10.4081/hr.2012.e10.
Palandri, F., Polverelli, N., Lifrieri, F., Catani, L., Giannini, M. B., Baccarani, M., & Vianelli, N. (2012). Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency. Hematology reports, 4(2), e10. https://doi.org/10.4081/hr.2012.e10
Palandri, Francesca, et al. "Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency." Hematology reports vol. 4,2 (2012): e10. doi: https://doi.org/10.4081/hr.2012.e10
Palandri F, Polverelli N, Lifrieri F, Catani L, Giannini MB, Baccarani M, Vianelli N. Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency. Hematol Rep. 2012 May 10;4(2):e10. doi: 10.4081/hr.2012.e10. Epub 2012 Jun 26. PMID: 22826792; PMCID: PMC3401131.
Copy Download .nbib Format: NLM
A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key.

Frontiers in pediatrics

Ferdjallah A, Young JH, MacMillan ML.
PMID: 34386464
Front Pediatr. 2021 Jul 27;9:634449. doi: 10.3389/fped.2021.634449. eCollection 2021.

Despite major advances in antimicrobial prophylaxis and therapy, opportunistic infections remain a major cause of morbidity and mortality after pediatric hematopoietic cell transplant (HCT). Risk factors associated with the development of opportunistic infections include the patient's underlying disease, previous...

Cite
Ferdjallah A, Young JH, MacMillan ML. A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key. Front Pediatr. 2021;9:634449doi: 10.3389/fped.2021.634449.
Ferdjallah, A., Young, J. H., & MacMillan, M. L. (2021). A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key. Frontiers in pediatrics, 9634449. https://doi.org/10.3389/fped.2021.634449
Ferdjallah, Asmaa, et al. "A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key." Frontiers in pediatrics vol. 9 (2021): 634449. doi: https://doi.org/10.3389/fped.2021.634449
Ferdjallah A, Young JH, MacMillan ML. A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key. Front Pediatr. 2021 Jul 27;9:634449. doi: 10.3389/fped.2021.634449. eCollection 2021. PMID: 34386464; PMCID: PMC8353083.
Copy Download .nbib Format: NLM
ANTIPHOSPHOLIPID ANTIBODIES DO NOT PREDICT DAMAGE IN SLE PATIENTS IN THE XXI CENTURY. AN OBSERVATIONAL STUDY FROM THE LUPUS-CRUCES COHORT.

Rheumatology (Oxford, England)

Ugarte A, Garcia de Bustos A, Ruiz-Arruza I, Soto-Peleteiro A, Martin-Iglesias D, Gonzalez-Echavarri C, Ruiz-Irastorza G.
PMID: 33769455
Rheumatology (Oxford). 2021 Mar 26; doi: 10.1093/rheumatology/keab307. Epub 2021 Mar 26.

OBJECTIVE: To compare the influence of antiphospholipid antibodies (aPL) on global and cardiovascular damage in patients with systemic lupus erythematosus (SLE) diagnosed before and after year 2000.METHODS: 286 patients from the Lupus-Cruces cohort with a minimum follow-up of 5...

Cite
Ugarte A, Garcia de Bustos A, Ruiz-Arruza I, et al. ANTIPHOSPHOLIPID ANTIBODIES DO NOT PREDICT DAMAGE IN SLE PATIENTS IN THE XXI CENTURY. AN OBSERVATIONAL STUDY FROM THE LUPUS-CRUCES COHORT. Rheumatology (Oxford). 2021;doi: 10.1093/rheumatology/keab307.
Ugarte, A., Garcia de Bustos, A., Ruiz-Arruza, I., Soto-Peleteiro, A., Martin-Iglesias, D., Gonzalez-Echavarri, C., & Ruiz-Irastorza, G. (2021). ANTIPHOSPHOLIPID ANTIBODIES DO NOT PREDICT DAMAGE IN SLE PATIENTS IN THE XXI CENTURY. AN OBSERVATIONAL STUDY FROM THE LUPUS-CRUCES COHORT. Rheumatology (Oxford, England), . https://doi.org/10.1093/rheumatology/keab307
Ugarte, Amaia, et al. "ANTIPHOSPHOLIPID ANTIBODIES DO NOT PREDICT DAMAGE IN SLE PATIENTS IN THE XXI CENTURY. AN OBSERVATIONAL STUDY FROM THE LUPUS-CRUCES COHORT." Rheumatology (Oxford, England) vol. (2021). doi: https://doi.org/10.1093/rheumatology/keab307
Ugarte A, Garcia de Bustos A, Ruiz-Arruza I, Soto-Peleteiro A, Martin-Iglesias D, Gonzalez-Echavarri C, Ruiz-Irastorza G. ANTIPHOSPHOLIPID ANTIBODIES DO NOT PREDICT DAMAGE IN SLE PATIENTS IN THE XXI CENTURY. AN OBSERVATIONAL STUDY FROM THE LUPUS-CRUCES COHORT. Rheumatology (Oxford). 2021 Mar 26; doi: 10.1093/rheumatology/keab307. Epub 2021 Mar 26. PMID: 33769455.
Copy Download .nbib Format: NLM
Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies.

Clinical reviews in allergy & immunology

Zhao W, Wang J, Zhu H, Pan M.
PMID: 34350539
Clin Rev Allergy Immunol. 2021 Aug 04; doi: 10.1007/s12016-021-08882-1. Epub 2021 Aug 04.

Pemphigus is a severe autoimmune bullous dermatosis that affects the skin and/or mucosa, and it may be life-threatening without proper treatment. The guidelines and/or consensus statements for treatment vary widely between groups. We selected 6 guidelines and consensus statements...

Cite
Zhao W, Wang J, Zhu H, et al. Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies. Clin Rev Allergy Immunol. 2021;doi: 10.1007/s12016-021-08882-1.
Zhao, W., Wang, J., Zhu, H., & Pan, M. (2021). Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies. Clinical reviews in allergy & immunology, . https://doi.org/10.1007/s12016-021-08882-1
Zhao, Wenzhe, et al. "Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies." Clinical reviews in allergy & immunology vol. (2021). doi: https://doi.org/10.1007/s12016-021-08882-1
Zhao W, Wang J, Zhu H, Pan M. Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies. Clin Rev Allergy Immunol. 2021 Aug 04; doi: 10.1007/s12016-021-08882-1. Epub 2021 Aug 04. PMID: 34350539.
Copy Download .nbib Format: NLM
Summary report of seven cases of COVID-19 infection in renal transplant recipients.

Transplant immunology

Wang T, Qiu T, Yuan Y, Chen Z, Ma X, Zhang L, Jin Z, Zou J, Zhang Y, Zhou J.
PMID: 34384886
Transpl Immunol. 2021 Dec;69:101445. doi: 10.1016/j.trim.2021.101445. Epub 2021 Aug 10.

The coronavirus disease 2019 (COVID-19) has swept the world, posing a serious threat to people's lives and health. Several cases of COVID-19 infection in renal transplant recipients (RTRs) have been reported, but the treatment and prognosis have not been...

Cite
Wang T, Qiu T, Yuan Y, et al. Summary report of seven cases of COVID-19 infection in renal transplant recipients. Transpl Immunol. 2021;69:101445doi: 10.1016/j.trim.2021.101445.
Wang, T., Qiu, T., Yuan, Y., Chen, Z., Ma, X., Zhang, L., Jin, Z., Zou, J., Zhang, Y., & Zhou, J. (2021). Summary report of seven cases of COVID-19 infection in renal transplant recipients. Transplant immunology, 69101445. https://doi.org/10.1016/j.trim.2021.101445
Wang, Tianyu, et al. "Summary report of seven cases of COVID-19 infection in renal transplant recipients." Transplant immunology vol. 69 (2021): 101445. doi: https://doi.org/10.1016/j.trim.2021.101445
Wang T, Qiu T, Yuan Y, Chen Z, Ma X, Zhang L, Jin Z, Zou J, Zhang Y, Zhou J. Summary report of seven cases of COVID-19 infection in renal transplant recipients. Transpl Immunol. 2021 Dec;69:101445. doi: 10.1016/j.trim.2021.101445. Epub 2021 Aug 10. PMID: 34384886; PMCID: PMC8352666.
Copy Download .nbib Format: NLM
Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis.

Pediatric nephrology (Berlin, Germany)

Qiu S, Zhang H, Yu S, Yang Q, Zhang G, Yang H, Li Q, Wang M.
PMID: 34379208
Pediatr Nephrol. 2021 Aug 11; doi: 10.1007/s00467-021-05164-y. Epub 2021 Aug 11.

BACKGROUND: Pediatric lupus nephritis (pLN) is one of the most refractory secondary kidney diseases in childhood. The treat-to-target (T2T) strategy has become the standard treatment for systemic lupus erythematosus (SLE). This study reviewed clinical features, overall remission status, and...

Cite
Qiu S, Zhang H, Yu S, et al. Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis. Pediatr Nephrol. 2021;doi: 10.1007/s00467-021-05164-y.
Qiu, S., Zhang, H., Yu, S., Yang, Q., Zhang, G., Yang, H., Li, Q., & Wang, M. (2021). Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis. Pediatric nephrology (Berlin, Germany), . https://doi.org/10.1007/s00467-021-05164-y
Qiu, Shiyuan, et al. "Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis." Pediatric nephrology (Berlin, Germany) vol. (2021). doi: https://doi.org/10.1007/s00467-021-05164-y
Qiu S, Zhang H, Yu S, Yang Q, Zhang G, Yang H, Li Q, Wang M. Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis. Pediatr Nephrol. 2021 Aug 11; doi: 10.1007/s00467-021-05164-y. Epub 2021 Aug 11. PMID: 34379208.
Copy Download .nbib Format: NLM
Bilateral juxtapapillary choroidal neovascularization secondary to Birdshot chorioretinopathy-case report.

Clinical case reports

Vidas Pauk S, Vukojević N, Jandroković S, Kalauz M, Tomić M, Masnec S, Škegro I, Mrazovac Zimak D.
PMID: 34429993
Clin Case Rep. 2021 Aug 16;9(8):e04601. doi: 10.1002/ccr3.4601. eCollection 2021 Aug.

Central vision loss, photopsia, floaters, and macular edema in a highly myopic patient can easily be misinterpreted as high myopia complications. In atypical cases, detailed examination and a thorough diagnostic workup are required to establish the proper diagnosis, which...

Cite
Vidas Pauk S, Vukojević N, Jandroković S, et al. Bilateral juxtapapillary choroidal neovascularization secondary to Birdshot chorioretinopathy-case report. Clin Case Rep. 2021;9(8):e04601doi: 10.1002/ccr3.4601.
Vidas Pauk, S., Vukojević, N., Jandroković, S., Kalauz, M., Tomić, M., Masnec, S., Škegro, I., & Mrazovac Zimak, D. (2021). Bilateral juxtapapillary choroidal neovascularization secondary to Birdshot chorioretinopathy-case report. Clinical case reports, 9(8), e04601. https://doi.org/10.1002/ccr3.4601
Vidas Pauk, Sania, et al. "Bilateral juxtapapillary choroidal neovascularization secondary to Birdshot chorioretinopathy-case report." Clinical case reports vol. 9,8 (2021): e04601. doi: https://doi.org/10.1002/ccr3.4601
Vidas Pauk S, Vukojević N, Jandroković S, Kalauz M, Tomić M, Masnec S, Škegro I, Mrazovac Zimak D. Bilateral juxtapapillary choroidal neovascularization secondary to Birdshot chorioretinopathy-case report. Clin Case Rep. 2021 Aug 16;9(8):e04601. doi: 10.1002/ccr3.4601. eCollection 2021 Aug. PMID: 34429993; PMCID: PMC8365546.
Copy Download .nbib Format: NLM
Showing 925 to 936 of 936 entries